Trials / Completed
CompletedNCT05482503
Clinical Investigation to Evaluate the Effectiveness and Safety of ECG App
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 673 (actual)
- Sponsor
- Huawei Device Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to verify the effectiveness and safety of the Huawei Device software (ECG APP), which can be used to analyze, store and display the ECG data transmitted by the single-lead ECG acquisition device. The software can be used for the analysis of sinus rhythm, atrial fibrillation, and premature beats(ventricular premature beats and atrial premature beats) in adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | 12-Lead ECG(I-lead) | All participants will simultaneously record 12-lead ECGs(I-lead) |
Timeline
- Start date
- 2021-04-02
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
- First posted
- 2022-08-01
- Last updated
- 2022-08-02
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05482503. Inclusion in this directory is not an endorsement.